Medical Management of BPH: Role of Plant Extracts

EAU-EBU Update Series

Volumn 5, Issue 5, 2007, Pages 197-205

  Madersbacher, Stephan ^a   Ponholzer, Anton ^a   Berger, Ingrid ^a   Marszalek, Martin ^a  

^a Donauspital ^*  (Austria)

Author keywords

Guidelines; Lower urinary tract symptoms; LUTS; Medical therapy; Meta analysis; Plant extracts

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; AROMATASE; AZUPROSTAT; BAZOTON UNO; CAMPESTEROL; CERNITIN; FATTY ACID DERIVATIVE; FINASTERIDE; HYPOXIS ROOPERI EXTRACT; LECTIN; LIGNIN; LUPEOL; PHENOL DERIVATIVE; PHYTOSTEROL; PLACEBO; PLANT EXTRACT; PLANT MEDICINAL PRODUCT; PROSTA FINK FORTE; PROSTAGLANDIN; PROSTAGUTT FORTE; PROSTATE SPECIFIC ANTIGEN; PYGEUM AFRICANUM EXTRACT; SABAL EXTRACT; SITOSTEROL; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE INHIBITOR; STEROL DERIVATIVE; STIGMASTEROL; TAMSULOSIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; URTICA DIOICA EXTRACT; URTICA EXTRACT;

ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; DRUG POTENTIATION; HUMAN; HYPOXIS; HYPOXIS ROOPERI; LONGITUDINAL STUDY; LOWER URINARY TRACT SYMPTOM; MANAGED CARE; META ANALYSIS; MICTURITION DISORDER; PRACTICE GUIDELINE; PROSPECTIVE STUDY; PROSTAGLANDIN SYNTHESIS INHIBITION; PROSTATE DISEASE; PROSTATE HYPERTROPHY; PROTEIN SYNTHESIS INHIBITION; PUMPKIN; PYGEUM; QUALITY OF LIFE; REVIEW; RYE; SABAL; SYSTEMATIC REVIEW; URTICA DIOICA; WORLD HEALTH ORGANIZATION;

EID: 34548010064     PISSN: 18712592     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eeus.2007.04.004     Document Type: Review

References (28)

1. Madersbacher S., Schatzl G., Brössner C., and Dreikorn K. Phytotherapy for BPS. Which products can still be prescribed. Urologe [A] 44 (2005) 513-520
2. Berges R.R., and Pientka L. Management of the BPH syndrome in Germany: who is treated and how?. Eur Urol 36 Suppl 3 (1999) 21-27
3. Hutchison A., Farmer R., Verhamme K., Berges R., and Navarrete R.V. The efficacy of drugs for the treatment of LUTS/BPH, a study in 6 European countries. Eur Urol 51 (2007) 207-216
4. In: Chatelain C., Denis L., Foo K.T., Khoury S., and McConnell (Eds). Proceedings of the 5th International Consultation on Benign Prostatic Hyperplasia (BPH) (2001), Plymbridge Distributors, Plymouth
5. Schagen van Leeuwen J.H., Castro R., Busse M., and Bemelmans B.L.H. The placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms. Eur Urol 50 (2006) 440-453
6. Madersbacher S., Marszalek M., Lackner J., Berger P., and Schatzl G. The long-term outcome of medical therapy for BPH. Eur Urol 51 (2007) 1522-1533
7. Emberton M. Patient-led management of BPH: from watchful waiting to self-management of LUTS. Eur Urol Suppl 5 (2006) 704-709
8. Dreikorn K., Lowe F., Borkowski A., et al. Other medical therapies. In: Chatelain C., Denis L., Foo K.T., Khoury S., and McConnell (Eds). Proceedings of the 5th International Consultation on Benign Prostatic Hyperplasia (BPH) (2001), Plymbridge Distributors, Plymouth 479-511
9. Meyer J.P., and Gillatt D.A. Alternative medications for benign prostatic hyperplasia available on the Internet: a review of the evidence for their use. BJU Int 90 (2002) 41-44
10. ®) with finasteride in the treatment of benign prostate hyperplasia: a randomised international study of 1.098 patients. The Prostate 29 (1996) 231-240
11. Debruyne F., Koch G., Boyle P., Calais da Silva F., Gillenwater J.G., Hamdy F.C., et al. Comparison of a phytotherapeutic agent (Permixon) with an α-blocker (tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomised international study. Eur Urol 41 (2002) 497-507
12. Boyle P., Robertson C., Lowe F., and Roehrborn C. Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia. BJU Int 93 (2004) 751-756
13. Bent S., Kane C., Shinohara K., Neuhaus J., Hudes E.S., Goldberg H., et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med 346 (2006) 557-566
14. Wilt T.J., Ishani A., Stark G., MacDonald R., Lau J., and Mulrow C. Saw palmetto extracts for treatment of benign prostatic hyperplasia. JAMA 280 (1998) 1604-1609
15. Lowe F.C., Dreikorn K., Borkowski A., Braeckman J., Denis L., Ferrari P., et al. Review of recent placebo-controlled trials utilizing phytotherapeutic agents for treatment of BPH. Prostate 37 (1998) 187-193
16. Berges R.R., Windeler J., Trampisch H.J., Senge T., and and the ß-sitosterol study group. Randomised, placebo-controlled, double-blind clinical trial of ß-sitosterol in patients with benign prostatic hyperplasia. The Lancet 345 (1995) 1529-1532
17. Klippel K.F., Hiltl D.M., Schipp B., and for the German BPH-Phyto study group. A multicentric, placebo-controlled, double-blind clinical trial of ß-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. Br J Urol 80 (1997) 427-432
18. Wilt T.J., McDonald R., and Ishani A. ß-sitosterol for the treatment of benign prostatic hyperplasia: a systematic review. BJU Int 83 (1999) 976-983
19. ®-uno) in long-term treatment of benign prostatic syndrome (BPS). Results of a randomized, double-blind, placebo-controlled multicenter study after 12 months. Urologe [A] 43 (2004) 302-306
20. Bach D und der interdisziplinärer Arbeitskreis Prostata. Placebokontrollierte Langzeittherapiestudie mit Kürbissamenextrakt bei BPH-bedingten Miktionsbeschwerden. Urologe [B] 2000;40:437-43.
21. Buck A.C., Cox R., Rees R.W.M., Ebeling L., and John A. Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen-extract Cernilton: a double-blind, placebo-controlled study. Br J Urol 66 (1990) 398-404
22. MacDonald R., Ishani A., Rutks I., and Wilt T.J. A systematic review of Cernilton for the treatment of benign prostatic hyperplasia. BJU Int 85 (1999) 836-841
23. Ishani A., MacDonald R., Nelson D., Rutks I., and Wilt T.J. Pygeum africanum for the treatment of patients with benign prostatic hyperplasia: a systematic review and quantitative meta-analysis. Am J Med 109 (2000) 654-664
24. Sökeland J., and Albrecht J. Combined Saabal and Urtica extract vs finasteride in BPH (alken stage I-II). Urologe [A] 36 (1997) 327-333
25. Engelmann, Walther C., Bondarenko B., Funk P., and Schläfke S. Efficacy and safety of a combination of sabal and urtica extract in lower urinary tract symptoms. Arzneimittelforschung 56 (2006) 222-229
26. Madersbacher S., Alivizatos G., Nordling J., Rioja Sanz C., Emberton M., and de la Rosette J.J.M.C.H. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 46 (2004) 547-554
27. AUA Practice Guidelines Committee. AUA guidelines on management of benign prostatic hyperplasia Chapter 1: diagnosis and treatment recommendations. J Urol 170 (2003) 530-547
28. Berges R., Dreikorn K., Höfner K., Jonas U., Laval K.U., Madersbacher S., et al. Leitlinien der Deutschen Urologen zur Therapie des benignen Prostatasyndroms (BPS). Urologe [A] 42 (2003) 722-738